Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial
European Respiratory Journal · 2026-08 · 68 (2) · 2501431
DOI: 10.1183/13993003.01431-2025 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Respiratory Journal, online erschienen am 04.06.2026. Verfasst von Marlies van Dijk und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands m.van.dijk05@umcg.nl. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Dyspnea, Morphine, Fentanyl. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Astma Bestrijding, Innovatiefonds Zorgverzekeraars.
Themen: COPD
Abstract (Originalsprache)
Background
One of the most prevalent and impactful symptoms in COPD is persistent dyspnoea, occurring in the majority of patients with advanced COPD. Opioids, mostly morphine, have been investigated and suggested as treatment in palliative care guidelines. However, in recent years multiple trials on morphine for persistent dyspnoea have shown no clinical benefit, and there are concerns regarding adverse events. Transdermal fentanyl has not yet been investigated for this indication.
Methods
We performed a multicentre, crossover, double-dummy randomised controlled trial, investigating transdermal fentanyl (12 μg·h −1 ), morphine (10 mg per os twice daily) and placebo, during three treatment periods of 2 weeks (including a 3-day washout period). Patients with persistent dyspnoea despite optimal therapy and modified Medical Research Council dyspnoea scale score ≥3 caused by COPD, forced expiratory volume in 1 s (FEV 1 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands m.van.dijk05@umcg.nl.
- Groningen Research Institute of Asthma and COPD (GRIAC), University of Groningen, Groningen, The Netherlands.
- Department of Pulmonary Diseases, Spaarne Gasthuis, Haarlem, The Netherlands.
- Department of Pulmonary Diseases, Medisch Spectrum Twente, Enschede, The Netherlands.
- Department of Pulmonary Diseases, Ikazia Ziekenhuis, Rotterdam, The Netherlands.
- Department of Pulmonary Diseases, Wilhelmina Ziekenhuis Assen, Assen, The Netherlands.
ORCID-Profile: Marlies van Dijk, Jan-Willem K van den Berg, Huib A M Kerstjens
Förderung
- Stichting Astma Bestrijding
- Innovatiefonds Zorgverzekeraars
Zitieren
APA
van Dijk, M., Mooren, K. J. M., van Beurden-Moeskops, W., Heller-Baan, R., de Hosson, S. M., Pieterman, R. M., Lam-Wong, W. Y., Peters, L., Pool, K., van den Berg, J. K., & Kerstjens, H. A. M. (2026). Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial. European Respiratory Journal, 68(2), 2501431. https://doi.org/10.1183/13993003.01431-2025
Vancouver
van Dijk M, Mooren KJM, van Beurden-Moeskops W, Heller-Baan R, de Hosson SM, Pieterman RM, et al. Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial. European Respiratory Journal. 2026;68(2):2501431. doi:10.1183/13993003.01431-2025
BibTeX
@article{vanDijk2026,
author = {van Dijk, Marlies and Mooren, Kris J M and van Beurden-Moeskops, Wendy and Heller-Baan, Roxane and de Hosson, Sander M and Pieterman, Remge M and Lam-Wong, Wai Yee and Peters, Liesbeth and Pool, Karin and van den Berg, Jan-Willem K and Kerstjens, Huib A M},
title = {Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial},
journal = {European Respiratory Journal},
year = {2026},
volume = {68},
number = {2},
pages = {2501431},
doi = {10.1183/13993003.01431-2025}
}
EUVIMED